Adalimumab for the treatment of juvenile idiopathic arthritis
Status Discontinued
Decision Selected
Process STA pre-2018
Referral date 01 June 2008
Topic area
  • Musculoskeletal

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
1 July 2011 Following on from the licence extension for adalimumab for juvenile idiopathic arthritis an additional draft scope consultation was conducted in November 2010. As a result of the consultation this topic will not be re referred onto the technology appraisals work programme. Please see the Block Scoping Report for further information
23 December 2008 Please note that this topic has been removed from the technology appraisals work programme.
22 September 2008 The above topic was referred to NICE as part of the 17th wave referrals. Following an update on the anticipated licence for adalimumab in this therapeutic area, limiting the use of this drug to a small population with juvenile idiopathic arthritis, we have concluded that further discussions with the Department of Health are required to establish how best to progress this appraisal.

We are therefore suspending this single technology appraisal whilst we consider the next steps. Please be assured that we will update you with further information once we have finalised our discussions.

For further information on our processes and methods, please see our CHTE processes and methods manual